List of Excipients in Branded Drug ACETAMINOPHEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	ACETAMINOPHEN	acetaminophen	0143-9386	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	ACETAMINOPHEN	acetaminophen	0143-9386	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	ACETAMINOPHEN	acetaminophen	0143-9386	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	ACETAMINOPHEN	acetaminophen	0143-9386	SODIUM HYDROXIDE

Generic Drugs Containing ACETAMINOPHEN

Company	Ingredient	NDC	Excipient
Walgreen Company	acetaminophen	0363-0334	CELLULOSE, MICROCRYSTALLINE
Walgreen Company	acetaminophen	0363-0334	CROSCARMELLOSE SODIUM
Walgreen Company	acetaminophen	0363-0334	HYPROMELLOSE
Walgreen Company	acetaminophen	0363-0334	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ACETAMINOPHEN?

# Of NDCs	Excipient
8	CARNAUBA WAX
80	CELLULOSE, MICROCRYSTALLINE
1	COTTONSEED ACID
5	COTTONSEED OIL

Acetaminophen Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Acetaminophen is a mature, low-cost analgesic and antipyretic with no meaningful remaining composition-of-matter exclusivity. Commercial value is concentrated in formulation performance, dosing convenience, pediatric safety, combination products, manufacturing efficiency, branded consumer health, and differentiated delivery systems. Excipients can support product differentiation, but they rarely create durable market protection unless linked to a demonstrable performance advantage and a defensible patent claim.

What is the regulatory and commercial status of acetaminophen?

Acetaminophen is marketed in the United States as an over-the-counter analgesic and antipyretic, as a prescription ingredient in combination products, and as an intravenous formulation. FDA regulates OTC acetaminophen primarily under the internal analgesic, antipyretic, and antirheumatic drug framework, including the acetaminophen labeling and dosing requirements in 21 C.F.R. § 201.326 and the OTC monograph system established under the CARES Act [1, 2].

Product category	Principal regulatory route	Commercial position
Immediate-release tablets and caplets	OTC monograph or approved application	Highly commoditized
Gelcaps and softgels	OTC monograph or approved application	Differentiated by swallowability and onset claims
Chewables and orally disintegrating tablets	OTC monograph or approved application	Pediatric and convenience opportunity
Oral liquids and suspensions	OTC monograph or approved application	Pediatric and caregiver-focused
Extended-release tablets	Approved application, depending on product	Premium formulation segment
Intravenous injection	NDA or ANDA	Hospital and perioperative market
Prescription opioid-acetaminophen combinations	NDA or ANDA	Generic-dominated, with safety-driven dose constraints
Topical or transdermal products	Product-specific regulatory pathway	Limited acetaminophen precedent and higher development risk

Acetaminophen is not a biologic. Biosimilar risk is therefore not applicable. Competitive risk comes from generics, private-label products, branded OTC products, NSAIDs, combination analgesics, and non-drug alternatives.

When did acetaminophen lose patent exclusivity?

Acetaminophen’s active ingredient and basic analgesic use are long off patent. The molecule was commercialized in the United States in the mid-20th century, and any original composition, synthesis, and basic therapeutic-use patents have expired.

There is no current composition-of-matter exclusivity for acetaminophen in the United States. Product-level protection can still arise from:

• Extended-release matrices
• Abuse-deterrent or tamper-resistant combinations
• Novel liquid or suspension systems
• Orally disintegrating dosage forms
• Device-enabled delivery
• Combination products
• Manufacturing processes
• Stability systems
• Pediatric dosing technologies

These rights are narrower than compound patents and generally protect a defined formulation or manufacturing method rather than acetaminophen itself.

What patents protect acetaminophen products?

Standalone acetaminophen tablets, capsules, caplets, and ordinary oral liquids have limited patent protection because the dosage forms and excipient classes are conventional. A formulation patent must generally claim a specific composition, process, release profile, stability result, particle engineering approach, or delivery mechanism.

The commercial patent landscape should be separated into four groups.

Patent category	Typical claim subject	Strategic value
Active ingredient patents	Acetaminophen molecule or core use	None remaining
Formulation patents	Release profile, excipient ratio, dosage form	Moderate if performance is difficult to reproduce
Method-of-use patents	Specific patient population, dosing regimen, or treatment setting	Usually narrow and difficult to enforce for OTC use
Manufacturing patents	Granulation, coating, compression, impurity control, or scale-up process	Valuable where process replication is difficult

Orange Book relevance depends on the product. FDA-approved prescription acetaminophen products and combinations can have patent and exclusivity records. OTC monograph products generally do not use the Orange Book as the principal source of market authorization or patent disclosure. The FDA Orange Book therefore does not provide a complete map of commercial acetaminophen formulation rights [3].

How strong is the acetaminophen patent estate?

The standalone acetaminophen patent estate is weak. Its main commercial barriers are scale, regulatory compliance, brand recognition, supply reliability, manufacturing know-how, and retail distribution.

A differentiated formulation can have a stronger position if it satisfies four conditions:

1. The excipient system produces a measurable benefit.
2. The benefit is relevant to a high-value customer segment.
3. Competitors cannot reproduce the result through routine substitution.
4. The claim covers a commercially important product configuration.

Broad claims to ordinary binders, disintegrants, sweeteners, lubricants, or coatings are unlikely to produce durable exclusivity. Narrow claims to a specific ratio, process sequence, particle architecture, or release profile have greater potential.

Which excipients are strategically important for acetaminophen?

Excipient selection should follow the target dosage form and commercial claim. The objective is not to maximize the number of excipients. It is to create a robust product with acceptable cost, stability, manufacturability, sensory performance, and regulatory status.

Product objective	Relevant excipient classes	Commercial rationale
Fast tablet disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid dispersion and perceived onset
High tablet strength	Microcrystalline cellulose, copovidone, povidone	Improves compression and reduces friability
Better swallowability	Film coatings, polyethylene glycol, hypromellose	Supports premium caplet and gelcap positioning
Taste masking	Ion-exchange resins, polymer coatings, sweeteners, flavors	Important for pediatric liquids and chewables
Liquid stability	Suspending agents, buffers, preservatives, wetting agents	Supports dose uniformity and shelf life
Extended release	Hydrophilic polymers, lipid matrices, insoluble polymers	Creates a differentiated dosing profile
Effervescent delivery	Acids, carbonates, bicarbonates, lubricants	Enables rapid dispersion and convenience
ODT performance	Porous fillers, superdisintegrants, mannitol, specialized binders	Supports low-water or rapid-dissolve formats
IV stability	Tonicity agents, pH adjusters, chelators, nitrogen control	Critical for parenteral stability and impurity control
Pediatric acceptability	Sweeteners, flavors, viscosity modifiers, taste masks	Supports adherence and caregiver preference

All excipients must be evaluated against FDA’s Inactive Ingredient Database, applicable USP-NF standards, safety exposure, route-specific precedent, and the intended maximum daily dose [4, 5]. An excipient acceptable in a tablet may require separate justification in an oral liquid or intravenous product.

What formulation patents are most commercially attractive?

Extended-release acetaminophen

Extended-release products offer the clearest formulation-led opportunity because dosing frequency can support a premium. The technical challenge is controlling release across varying gastrointestinal conditions while avoiding dose dumping.

Promising systems include:

• Hydrophilic polymer matrices
• Bilayer tablets with immediate- and sustained-release components
• Multiparticulate capsules
• Coated pellets
• Lipid-polymer matrices
• Osmotic or membrane-controlled systems

The patent position is strongest when the claimed system links a defined excipient structure to a reproducible pharmacokinetic profile. A claim limited to “acetaminophen with a sustained-release polymer” is more vulnerable than a claim specifying polymer grade, loading, coating thickness, dissolution limits, and manufacturing conditions.

Pediatric liquids and chewables

Pediatric formulations have commercial value despite low active-ingredient cost. Parents and caregivers prioritize dosing accuracy, palatability, preservative systems, and compatibility with dosing devices.

Key opportunities include:

• Low-sugar or sugar-free liquids
• Alcohol-free systems
• Improved taste masking
• Reduced viscosity for syringe dosing
• Concentrated products that reduce administration volume
• Unit-dose sachets or ready-to-administer cups
• Chewables with improved mouthfeel
• Products designed for children with swallowing limitations

Pediatric products also carry regulatory risk. Concentration changes can create medication-error exposure. FDA has emphasized clear labeling, standardized dosing devices, and careful communication of milligrams and milliliters [1].

Orally disintegrating tablets

ODTs can target adults with dysphagia, pediatric users, travelers, and consumers seeking water-free dosing. Acetaminophen’s high dose requirement makes ODT development difficult because tablets can become large, friable, or unpleasant in the mouth.

Commercially viable ODT systems may use:

• Highly compressible mannitol
• Crospovidone or croscarmellose sodium
• Porous granules
• Taste-masking coatings
• Direct-compression excipient platforms
• Low-force compression processes

The strongest opportunity is not simply rapid disintegration. It is a combined performance package involving acceptable tablet size, mechanical strength, taste, packaging stability, and consistent disintegration.

Intravenous acetaminophen

Intravenous acetaminophen is a regulated hospital product with higher technical and quality barriers than OTC tablets. Formulation priorities include:

• Solution clarity
• Chemical stability
• Control of oxidative degradation
• Particulate limits
• Container compatibility
• Sterility assurance
• Dose flexibility
• Infusion-bag or vial usability

Manufacturing and quality systems can create meaningful barriers even when formulation patents are weak. Hospital contracts, shortage resilience, supply qualification, and procurement status may matter more than patent exclusivity.

What FDA regulatory issues affect acetaminophen excipient selection?

The main regulatory risks are dose accuracy, hepatotoxicity exposure, impurity formation, product concentration, and consumer comprehension.

Acetaminophen labeling must communicate maximum daily dosing and the risk of liver injury. Combination products create a specific risk because consumers may unknowingly take acetaminophen from multiple medicines. FDA has limited the amount of acetaminophen in prescription combination products containing opioids to 325 mg per dosage unit and has required stronger liver-injury warnings [6].

Excipient development should address:

• Maximum daily acetaminophen exposure
• Excipient exposure at the full labeled dose
• Preservative concentration in pediatric liquids
• Sugar and polyol content
• Sodium content in effervescent products
• Alcohol content
• Allergen and intolerance considerations
• Container-closure compatibility
• Extractables and leachables
• Dissolution and dose uniformity
• Stability-indicating impurity methods

For OTC products, the monograph route can reduce application burden when the product conforms to the applicable conditions. A novel dosage form, new route, unusual concentration, or unsupported claim may require an FDA application.

How many patents cover acetaminophen formulations?

No single public database gives a complete, current count of all acetaminophen formulation patents across jurisdictions and legal statuses. Patent families also include abandoned applications, expired rights, continuations, and claims directed to combination products rather than acetaminophen alone.

For commercial diligence, the relevant count is the number of live, enforceable claims covering the proposed product in each target jurisdiction. That count is usually much smaller than the number of documents returned by a keyword search.

A practical freedom-to-operate review should classify patent families by:

• Active ingredient and salt form
• Dosage form
• Excipient composition
• Dissolution profile
• Manufacturing process
• Combination partner
• Delivery device
• Geographic status
• Expiration date
• Patent-term adjustment or extension
• Claim scope after prosecution or litigation

The United States, European Union, Canada, Japan, Australia, Brazil, China, and India should be reviewed separately. Acetaminophen is globally commoditized, but formulation and manufacturing claims may have different filing and expiry profiles by country.

Are there Paragraph IV challenges involving acetaminophen?

Standalone OTC acetaminophen products generally do not create the same Paragraph IV profile as prescription drugs filed through an ANDA. Paragraph IV litigation becomes relevant when a generic applicant relies on an approved prescription product and certifies that listed patents are invalid, unenforceable, or not infringed under the Hatch-Waxman framework [7].

Potentially relevant products include:

• Prescription acetaminophen injection
• Prescription acetaminophen combinations
• Extended-release prescription products
• Products with patented delivery systems

For ordinary OTC acetaminophen tablets, the principal competitive mechanism is monograph compliance and private-label manufacturing rather than Paragraph IV litigation.

What patent litigation affects acetaminophen?

Current commercial disputes involving acetaminophen are more likely to concern combination products, manufacturing contracts, product liability, labeling, or supply issues than the core molecule.

Patent disputes may arise where a company claims:

• A particular extended-release profile
• A novel abuse-deterrent combination
• A proprietary delivery device
• A specialized liquid or suspension
• A manufacturing process that controls impurities
• A formulation that reduces dosing frequency

The litigation value of an acetaminophen patent depends on whether the accused product must practice the claimed formulation. A patent covering an optional excipient has limited leverage if competitors can achieve the same performance through non-infringing alternatives.

Which companies compete in acetaminophen products?

The competitive field has three layers.

Segment	Representative companies or brands	Basis of competition
Branded OTC	Kenvue’s Tylenol, Haleon’s Panadol in international markets	Brand, distribution, consumer trust
Store brand and generic	Perrigo, private-label manufacturers, regional generic producers	Price, retailer contracts, supply
Hospital and prescription	Generic injectable manufacturers and branded hospital suppliers	Quality, availability, procurement, compliance

Kenvue identifies Tylenol and related pain-relief products as major consumer health brands [8]. Haleon’s Panadol franchise has a substantial international presence, with market positioning that varies by country and dosage form [9].

Brand owners can monetize small formulation improvements through premium pricing, line extensions, differentiated packaging, and retailer placement. Generic manufacturers generally compete on cost, reliable supply, and regulatory execution.

What licensing deals and commercial partnerships exist?

Acetaminophen’s active ingredient is broadly available from multiple manufacturers, so licensing value generally resides in a delivery technology, branded franchise, manufacturing process, or geographic commercialization right.

Potentially valuable deal structures include:

• Licensing an extended-release platform
• Contract manufacturing of pediatric liquids
• Private-label supply agreements
• Regional rights for branded products
• Hospital supply contracts for intravenous products
• Co-development of dose-measuring devices
• Licensing of taste-masking technology
• Manufacturing technology transfers

Publicly disclosed licensing activity is more important at the brand and platform level than at the acetaminophen molecule level. A buyer should value a proposed deal on net sales, conversion cost, regulatory status, exclusivity by territory, minimum purchase obligations, and freedom to substitute excipients.

What generic entry risks exist for acetaminophen?

Generic entry risk is high for conventional acetaminophen products and lower for technically differentiated formats.

Product type	Generic entry risk	Main barrier
325 mg or 500 mg immediate-release tablet	Very high	Minimal technical differentiation
Standard caplet or gelcap	Very high	Established manufacturing methods
Oral liquid	High	Taste, stability, and packaging execution
Chewable	High to moderate	Palatability and tablet robustness
ODT	Moderate	Dose loading and sensory performance
Extended release	Moderate	Bioequivalence and dissolution control
Intravenous injection	Moderate	Sterile manufacturing and supply qualification
Device-linked product	Moderate to low	Device integration and regulatory requirements

The most defensible commercial position typically combines a formulation right with a non-patent barrier. Examples include validated pediatric tolerability, a reliable dosing device, qualified hospital supply, proprietary packaging, or a low-cost manufacturing process.

How does acetaminophen compare with ibuprofen?

Acetaminophen and ibuprofen compete directly in analgesic and antipyretic categories but support different excipient strategies.

Attribute	Acetaminophen	Ibuprofen
Primary positioning	Pain and fever reduction	Pain, fever, and inflammation
Key safety concern	Dose-related liver injury	Gastrointestinal, renal, and cardiovascular risks
Tablet formulation	High-dose loading can create large tablets	Solubility and dissolution can be challenging
Pediatric opportunity	Strong liquid and chewable market	Strong liquid and chewable market
Combination opportunity	Cold, flu, opioid, and migraine products	Cold, flu, and migraine products
Patent strength	Core molecule off patent	Core molecule off patent
Premium opportunity	ER, ODT, taste masking, IV	Solubility enhancement, softgels, liquid systems

Acetaminophen’s principal formulation problem is dose burden and safety communication. Ibuprofen’s principal technical problem is often solubility, dissolution, and gastrointestinal tolerability. The excipient platform should reflect those differences.

What commercial opportunities are most attractive?

The strongest opportunities are concentrated in defined customer problems rather than undifferentiated tablets.

High-potential opportunities

• Pediatric liquids with better taste and dose accuracy
• Sugar-free and low-volume liquid products
• Extended-release products with credible dosing convenience
• ODTs for dysphagia and water-free use
• Hospital-grade intravenous products with supply reliability
• Combination products with clear acetaminophen dose communication
• Private-label products using high-efficiency manufacturing
• Sustainable packaging and lower-material-dose systems
• Unit-dose products for travel, schools, and institutional care

Lower-potential opportunities

• Standard immediate-release tablets without a cost advantage
• Minor color or flavor changes
• Conventional excipient substitutions without performance improvement
• Broad patent claims directed only to routine excipient classes
• New products that increase concentration without improving dosing safety

Revenue exposure is greatest for established brands and retailer suppliers because acetaminophen products have high unit volume and low manufacturing cost. Public companies generally report acetaminophen within broader consumer health or pain-relief categories rather than as a standalone revenue line, limiting precise product-level revenue attribution [8, 9].

Key Takeaways

• Acetaminophen has no meaningful remaining composition-of-matter exclusivity.
• Conventional tablets and caplets face very high generic and private-label competition.
• Excipient value is highest in pediatric, extended-release, ODT, liquid, and intravenous products.
• Formulation patents must link composition to measurable performance to create meaningful protection.
• The Orange Book is relevant to approved prescription products but does not fully describe OTC acetaminophen competition.
• Paragraph IV exposure is product-specific and generally limited to approved prescription formulations and combinations.
• Biosimilar risk does not apply because acetaminophen is a small-molecule drug.
• Manufacturing capability, quality systems, distribution, and brand equity often provide stronger barriers than patents.
• The most attractive commercial strategy combines differentiated excipients with regulatory compliance, dose accuracy, and a defined consumer or institutional need.

FAQs About Acetaminophen Excipient Strategy

Can a new excipient create exclusivity for acetaminophen?

A new excipient alone rarely creates durable exclusivity. Protection is more credible when the excipient is part of a specific formulation that delivers unexpected stability, release, taste, bioavailability, or manufacturing performance.

What is the best excipient strategy for pediatric acetaminophen?

The priority is a palatable, dose-accurate, stable liquid or chewable product. Taste masking, viscosity control, preservative selection, and a calibrated dosing device are usually more commercially important than a novel tablet binder.

Can acetaminophen be developed as a transdermal product?

Transdermal development is technically difficult because acetaminophen must cross the skin at a therapeutically useful rate. Permeation enhancers, adhesive systems, drug loading, skin tolerability, and dose consistency create substantial development and regulatory barriers.

Does acetaminophen have orphan-drug potential?

Acetaminophen itself is not an orphan-drug opportunity for ordinary pain or fever indications. An orphan designation would require a qualifying rare disease use and an eligible clinical and regulatory strategy.

What is the most defensible acetaminophen formulation patent?

A patent combining a defined excipient system, manufacturing process, dissolution or release limits, and a demonstrated clinical or usability benefit is generally more defensible than a broad claim covering acetaminophen with a conventional excipient.

References

1. U.S. Food and Drug Administration. (2023). Acetaminophen: FDA information and safety communication. https://www.fda.gov
2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. § 201.326: Package labeling for acetaminophen-containing products. https://www.ecfr.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
6. U.S. Food and Drug Administration. (2011). FDA drug safety communication: Prescription acetaminophen products limited to 325 mg per dosage unit. https://www.fda.gov
7. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov
8. Kenvue Inc. (2024). Annual report. https://www.kenvue.com
9. Haleon plc. (2024). Annual report and financial statements. https://www.haleon.com